Treatment efficacy for adult persistent immune thrombocytopenia: a systematic review and network meta‐analysis
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Treatment efficacy for adult persistent immune thrombocytopenia: a systematic review and network meta‐analysis
Authors
Keywords
-
Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2019-08-19
DOI
10.1111/bjh.16161
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Eltrombopag versus romiplostim in treatment of adult patients with immune thrombocytopenia: A systematic review incorporating an indirect-comparison meta-analysis
- (2018) Jiaxing Zhang et al. PLoS One
- Systematic Literature Review of Treatments Used for Adult Immune Thrombocytopenia (ITP) in the Second-line Setting
- (2018) Lauren C. Bylsma et al. AMERICAN JOURNAL OF HEMATOLOGY
- Comparison of treatments for persistent/chronic immune thrombocytopenia: a systematic review and network meta-analysis
- (2018) Yasuyuki Arai et al. PLATELETS
- Have splenectomy rate and main outcomes of ITP changed after the introduction of new treatments? A monocentric study in the outpatient setting during 35 years
- (2016) Francesca Palandri et al. AMERICAN JOURNAL OF HEMATOLOGY
- Multicentre, randomised phase III study of the efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia
- (2016) Renchi Yang et al. BRITISH JOURNAL OF HAEMATOLOGY
- Tolerability and Efficacy of Eltrombopag in Chronic Immune Thrombocytopenia: Meta-Analysis of Randomized Controlled Trials
- (2016) Ahmed Saber Elgebaly et al. CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
- Efficacy and safety of thrombopoietin receptor agonists in patients with primary immune thrombocytopenia: A systematic review and meta-analysis
- (2016) Li Wang et al. Scientific Reports
- The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
- (2015) Brian Hutton et al. ANNALS OF INTERNAL MEDICINE
- A multicenter randomized open-label study of rituximab plus rhTPO vs rituximab in corticosteroid-resistant or relapsed ITP
- (2015) H. Zhou et al. BLOOD
- Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial
- (2015) Waleed Ghanima et al. LANCET
- Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis
- (2015) Shaan Chugh et al. Lancet Haematology
- The design-by-treatment interaction model: a unifying framework for modelling loop inconsistency in network meta-analysis
- (2015) Dan Jackson et al. Research Synthesis Methods
- A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia
- (2014) J. B. Bussel et al. BLOOD
- Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France
- (2014) G. Moulis et al. BLOOD
- Management of Primary Immune Thrombocytopenia, 2012: A Survey of Oklahoma Hematologists-Oncologists
- (2013) Kaelyn H. Lu et al. AMERICAN JOURNAL OF THE MEDICAL SCIENCES
- Graphical Tools for Network Meta-Analysis in STATA
- (2013) Anna Chaimani et al. PLoS One
- A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia
- (2012) D. M. Arnold et al. BLOOD
- How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment
- (2012) W. Ghanima et al. BLOOD
- A multicenter randomized controlled trial of recombinant human thrombopoietin treatment in patients with primary immune thrombocytopenia
- (2012) Shujie Wang et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- ROMIPLOSTIM AND ELTROMBOPAG FOR IMMUNE THROMBOCYTOPENIA: METHODS FOR INDIRECT COMPARISON
- (2012) Katy L. Cooper et al. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE
- A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia
- (2012) Y. TOMIYAMA et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies
- (2012) J. P. T. Higgins et al. Research Synthesis Methods
- The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia
- (2011) C. Neunert et al. BLOOD
- Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized Phase III clinical trial
- (2011) Yukari Shirasugi et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Pathophysiology and management of chronic immune thrombocytopenia: focusing on what matters
- (2010) Lisa J. Toltl et al. BRITISH JOURNAL OF HAEMATOLOGY
- Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study
- (2010) Gregory Cheng et al. LANCET
- Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia
- (2010) David J. Kuter et al. NEW ENGLAND JOURNAL OF MEDICINE
- International consensus report on the investigation and management of primary immune thrombocytopenia
- (2009) D. Provan et al. BLOOD
- Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial
- (2009) James B Bussel et al. LANCET
- Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group
- (2008) F. Rodeghiero et al. BLOOD
- Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial
- (2008) David J Kuter et al. LANCET
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started